AstraZeneca, other trouble besides Covid vaccine.
Markets have been negatively affected by the new tested cancer drug launched by the pharmaceutical giant. The drug, generated by studying a monoclonal antibody against cancer, has in fact disappointed expectations causing important repercussions on the share value.
Gianluca Cambareri of Tonucci & Partners, expert in commercial law and capital market, was interviewed by Panorama.
